Press releases

To stay up to date with our development, sign up for a subscription.

Subscribe

Bulletin from the annual general meeting in Sedana Medical AB (publ)

Regulatory

Today, the annual general meeting of Sedana Medical AB (publ) (SEDANA: FN Stockholm) was held. In order to counteract the spreading of the corona virus, the general meeting was held only through advance voting (so-called postal voting) in accordance…

Notice of Annual General Meeting in Sedana Medical AB (publ)

Regulatory

The shareholders in Sedana Medical AB (publ), reg. no. 556670-2519, are hereby given notice to attend the annual general meeting to be held Wednesday, 11 May 2022. In order to counteract the spreading of the corona virus, the board of directors of th…

Sedana Medical presents post hoc analysis at ISICEM

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that a post hoc analysis on the Sedaconda study will be presented as a poster at the world’s largest conference for intensive care and emergency medicine, ISICEM, in Brussels on March 22…

Sedana Medical’s first Sedaconda (isoflurane) shipments

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the first bottles of Sedaconda (isoflurane) have been delivered to customers. The first sales were made in the company’s largest market Germany.

Sedana Medical’s Sedaconda ACD recommended by NICE

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the National Institute for Health and Care Excellence (NICE) has issued positive guidance recommending Sedaconda ACD as a cost-saving option for delivering inhaled sedation in inten…

Sedana Medical appoints Johan Spetz as new CFO

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces the appointment of Johan Spetz as the company’s new Chief Financial Officer (CFO). Johan Spetz will take office no later than April 4, 2022, succeeding Susanne Andersson who will leave h…

Sedana Medical receives IND approval for US trials

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to initiate phase III pivotal clinical trials with its Sedaconda pro…

Sedana Medical applies for market approval in Italy

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has submitted an application for market approval for Sedaconda (isoflurane) for inhaled sedation in intensive care in Italy.

Sedana Medical submits IND for US clinical trials

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA), with the aim to commence its phase III pivotal clinical trials…